Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Assess the Efficacy and Safety of CDX-0159 in Patients With Chronic Spontaneous Urticaria

NCT05368285 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT05368285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05368285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Assess the Efficacy and Safety of CDX-0159 in Patients With Chronic Spontaneous Urticaria
Lead sponsor
Celldex Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
May 19, 2022
Completion date
December 20, 2024
Enrollment
208 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

chronic spontaneous urticaria